Overview of the Pharmaceutical Industry and New Drug Market Trends: Perspectives and Insights: DATAB

Overview of the Pharmaceutical Industry and New Drug Market Trends: Part I - Perspectives and Insights provides a comprehensive analysis of the global pharmaceutical industry, highlighting corporate rankings, market evolution, and long-term trends from 2013 to 2024.

This volume examines the performance of the top 30 pharmaceutical companies, tracking their sales, market shifts, and R&D strategies over 12 years. Key developments include:

• Pfizer regained the top position with COVID-19 vaccines after a temporary decline following the Viatris spin-off.

• Merck rose to 2nd place on the strength of Keytruda, approaching $30 billion in sales.

• Johnson & Johnson, driven by Stelara and Darzalex, climbed from 7th to 3rd place.

• AbbVie advanced after the Allergan merger, but patent expirations of Humira impacted its ranking.

• GLP-1 agonists propelled Eli Lilly and Novo Nordisk, reshaping mid-tier company rankings.

• Companies such as AstraZeneca, Sanofi, Novartis, Roche, and Takeda faced patent expirations, portfolio spin-offs, and competition from biosimilars, highlighting the industry's dynamic landscape.

By 2024, the top six companies exceeded $50 billion in annual sales, with Pfizer surpassing $60 billion, while the next tier reached $40 billion, leaving only Takeda and Amgen in the $30 billion range.

Industry Transformation Over Four Decades:
This book also traces long-term industry themes since 1985, summarizing target diseases, technological innovations, and management challenges in 10-year intervals, providing historical context to today's market dynamics.

Ideal for investors, industry analysts, researchers, and pharmaceutical professionals, this volume offers authoritative insights into market trends, corporate strategies, and the evolution of global pharmaceutical innovation.

DATABOOK 2024 - Part III provides an in-depth analysis of the global pharmaceutical industry with a focus on pharmacology classes. This volume explores the latest trends in prescription drugs, new drug development, and market dynamics across therapeutic areas.

Readers will gain comprehensive insights into:

• Market rankings of top prescription drugs worldwide

• Pharmacology class-specific sales and growth trends

• Pipeline developments and regulatory milestones

• Emerging opportunities in biologics, small molecules, and novel modalities

  Part IV - Pharmaceutical Companies. This volume provides a comprehensive analysis of 2024 new drug development from the top 30 global pharma companies, covering approvals, clinical studies, regulatory milestones, and business development activities.

  Key insights include:

• Global New Drug Market: 300 prescription products totaling $691 billion in 2024, up 8% YoY.

• Company Groups:

  • Top 10: Pfizer, Merck, J&J, AbbVie, AstraZeneca, Roche, Novartis, BMS, Eli Lilly, Sanofi

  • Mid-Tier: Novo Nordisk, GSK, Amgen, Takeda, Gilead, Bayer, Regeneron, Astellas, Daiichi Sankyo, Otsuka

  • Biotech & Others: Vertex, Biogen, Chugai, UCB, Eisai, Incyte, Lundbeck, Alnylam, Boehringer Ingelheim

• R&D Highlights: 28 initial approvals, 61 additional approvals, 135 clinical advances, and 9 licensing deals.

• Pipeline: 362 drugs across 572 Phase 3+ projects, with oncology and immunology as dominant focus areas.